In CML, FOXO3 plays an essential role for long-term maintenance of leukemia-initiating stem cells [10] that are resistant to tyrosine kinase inhibitor (TKI) therapy, preventing complete molecular response, and causing recurrence of CML [22]. The gene discussed is FOXO3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.